To boost the development of the biomedical industry, Zhangjiang AI New Drug R&D Alliance welcomes new members

In recent years, the potential of artificial intelligence in assisting the research and development of new drugs, reducing costs and increasing efficiency has rapidly emerged, becoming a mainstream trend in the development of the biomedical industry.

Two years ago, under the initiative and witness of Academicians Chen Kaixian, Jiang Hualiang and Rao Zihe of the Chinese Academy of Sciences, the Zhangjiang AI New Drug R&D Alliance was officially unveiled. On September 26, it was announced at the 2023 Zhangjiang Life Sciences International Innovation Summit - "2023 Zhangjiang AI Intelligent Drug Forum" that the Zhangjiang AI New Drug Research and Development Alliance "changed and expanded". The alliance's bureau made its debut, and 10 new force members joined to become the driving force. An important force in the construction of artificial intelligence new drug innovation ecosystem.

AI and biomedicine “two-way empowerment”

Developing rapidly, innovative results are launched every year

As an important link, the AI ​​Alliance is committed to promoting cross-border integration, data resource sharing, and technology iterative upgrades in the fields of AI and medicine. Our goal is to be based in Zhangjiang, facing Shanghai, and provide services for the construction of a nationwide artificial intelligence new drug innovation ecosystem

The list of the Zhangjiang AI New Drug R&D Alliance includes scientific research institutions such as the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, the Shanghai Institute of Advanced Studies of Zhejiang University, and Medicilon Biomedicine, the first CRO (pharmaceutical R&D outsourcing) on ​​the Science and Technology Innovation Board. There are also companies with obvious artificial intelligence characteristics such as Jingtai Technology, Yingsi Intelligent, and Shenzhen Technology

Liu Jian, co-chairman of the first alliance and president of Medicilon’s Drug Discovery Division, said that AI pharmaceuticals have developed rapidly after 2015, especially in Zhangjiang, Pudong, where many pharmaceutical companies have integrated AI technology and platforms. "Companies in the alliance launch innovative results every year. One of the purposes of the alliance is to integrate data sharing. Driven by the alliance, AI new drug research and development data is becoming more and more abundant, and AI models are constantly being optimized and iterated."

The AI ​​Alliance continues to emerge with innovative results, attracting more and more related companies to join. On the same day, 10 companies including Jitai Pharmaceuticals, Carbon Silicon Intelligence, Zhihua Technology, Xingkangyuan, Tianliang Intelligence, Zheyuan Technology, Ruizhi Pharmaceutical, Viva Biotech, Tenmai Pharmaceuticals, and Sozhi Biotech became new members of the AI ​​Alliance. The addition of new members not only injects new vitality into the alliance, but also encourages alliance member companies to continuously explore new applications of AI in the new drug research and development system

AI is releasing a huge “demonstration effect”

Jingtai Technology is one of the founding members of the AI ​​Alliance and participated in the establishment and development of the alliance. During this year's change, Dr. Ma Jian, co-founder and CEO of Jingtai Technology, was elected as the new co-chairman. At the AI ​​Alliance reelection ceremony, Rao Zihe, academician of the Chinese Academy of Sciences, awarded Dr. Ma Jian a co-chairman certificate. Yuan Tao, Party Secretary and Chairman of Zhangjiang Group, witnessed the reelection ceremony as chairman of the AI ​​Alliance. This marks that Zhangjiang AI New Drug R&D Alliance has entered a new stage of development

Jingtai Technology is one of the representative companies of artificial intelligence in Pudong. It has an automated laboratory workstation cluster at its Shanghai headquarters in Zhangjiang. The laboratory has more than 200 automated workstations and 5,000 square meters of intelligent automated laboratory. In addition, Jingtai Technology has more than 150 software and hardware R&D engineers and more than 300 scientists in related fields

“After 31 years of development, Zhangjiang has become a center of high-quality resources. Biomedicine, artificial intelligence, integrated circuits, intelligent manufacturing and other industries are highly concentrated here, with areas such as Medicine Valley, Medical Valley, Robot Valley, and Artificial Intelligence Island. It has become an industrial landmark, leading various vertical fields to the world stage. The Zhangjiang AI New Drug R&D Alliance was born in Zhangjiang. In the future, Jingtai will also further play its role in integrating and driving the AI ​​drug R&D industry chain and continue to be the source of new drug R&D. Innovation exploration and industrial application implementation." Dr. Ma Jian said.

As an emerging field that has emerged in recent years, artificial intelligence pharmaceuticals is showing great influence. Zhangjiang is actively seizing the advantages of combining artificial intelligence and medicine, attracting a number of global innovative companies to join this rapidly developing field

Source: Pudong Release

The above is the detailed content of To boost the development of the biomedical industry, Zhangjiang AI New Drug R&D Alliance welcomes new members. For more information, please follow other related articles on the PHP Chinese website!